1. Predictors of response to infliximab in patients with Crohn's disease
Mansour A. Parsi, Jean–Paul Achkar, Scott Richardson, Jeffry Katz, Jeffrey P. Hammel, Bret A. Lashner, Aaron Brzezinski 
Gastroenterology 
Volume 123, Issue 3, Pages (September 2002)
DOI: /gast
Copyright © 2002 American Gastroenterological Association Terms and Conditions

2. Fig. 1
(A) Effect of smoking and (B) concurrent immunosuppressive therapy on rate of response to infliximab. A: ■, Smoker; □, nonsmoker. B: ■, Immunosuppressive use; □, no immunosuppressive use.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

3. Fig. 2
(A) Effect of smoking and (B) concurrent immunosuppressive therapy on prolonged response (defined as response >2 months) to infliximab. A: ■, Smoker; □, nonsmoker. B: ■, Immunosuppressive use; □, no immunosuppressive use.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions